A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Arvinas Estrogen Receptor, Inc..
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
71actual
Sites
58
Countries
Belgium, Canada, China +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-19 | actual | When the study began enrolling |
| Primary completion | 2025-09-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-07 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: vepdegestrant — also filed as ARV-471 / PF07850327
- Drug: PF-07220060
Primary outcomes
what the primary-completion date above is the date OFPhase 1b: Number of Participants With Dose Limiting Toxicities
measured 28 days
Phase 2: Percentage of Participants With Objective Response by investigator assessment
measured Up to approximately 1 year
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed